Kolexia
Augereau Paule Oncologie médicale
Augereau Paule
Oncologie médicale
Ico - Site Paul Papin
Angers, France
110 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs de l'ovaire Carcinomes Tumeurs du sein triple-négatives Récidive tumorale locale Tumeurs du cerveau Tumeur du sein de l'homme Carcinome épithélial de l'ovaire

Collaborateurs

Voir plus
Frenel Jean-Sebastien
Frenel Jean-Sebastien
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Campone Mario
Campone Mario
Ico - Site Paul Papin, Angers, France
Patsouris Anne
Patsouris Anne
Ico - Site Paul Papin, Angers, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France

Industries

Voir plus
Pfizer
9 collaboration(s)
Dernière en 2022
AstraZeneca
7 collaboration(s)
Dernière en 2023
KANTAR PROFILES HEALTH
6 collaboration(s)
Dernière en 2022
MSD
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
BIOMEDE 2: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
Essai Clinique (Chimerix)   29 février 2024
VICTORIA: A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Essai Clinique (Centre Léon-Bérard)   12 février 2024
62P Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed glioblastoma multiforme: PAZOGLIO trial
Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT) 26 - 28 February 2024   01 février 2024
Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer.
JNCI cancer spectrum   19 décembre 2023
NeoTOP: Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Essai Clinique (Unicancer)   06 décembre 2023
CTNI-33. TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA
Abstracts from the 2023 Society for Neuro-Oncology’s 28th Annual Scientific Meeting and Education Day   10 novembre 2023
1062P Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
InTTercePT: Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Essai Clinique (Seagen)   21 septembre 2023
Intrathecal Catheter for Chemotherapy in Leptomeningeal Carcinomatosis From HER2-Negative Metastatic Breast Cancer.
Journal of breast cancer   08 septembre 2023